Optimal CGM Target Ranges for Non-Diabetics: A Clinical Interpretation Guide

For decades, blood glucose monitoring was reserved almost exclusively for people already diagnosed with diabetes. A once-yearly fasting blood glucose reading was considered sufficient for everyone else. That paradigm has fundamentally shifted. The rise of affordable continuous glucose monitors (CGMs) and a growing body of research on metabolic dysfunction before formal diabetes diagnosis have made it clear that waiting for a clinical threshold to be crossed is not the same as being metabolically healthy.

A CGM worn for 14 days produces over 2,000 individual glucose readings, compared to the single snapshot of an annual fasting test. It captures postprandial responses to specific foods, overnight glucose patterns, the impact of stress and sleep on metabolic regulation, and the speed of glucose return to baseline after a meal. For a non-diabetic, this data can reveal early warning patterns of insulin resistance, reactive hypoglycemia, and glycemic variability that are clinically invisible on standard lab work.

This guide explains how a CGM works, defines the 7 key glucose metrics a non-diabetic should monitor, provides evidence-based clinical targets for each, and describes the dietary and behavioral inputs that most powerfully move those numbers. As always, consult a qualified healthcare provider before initiating CGM-based health protocols, particularly if you have an existing medical condition or are taking medications that affect blood glucose.

What Is a Continuous Glucose Monitor and How Does It Work?

A continuous glucose monitor is a wearable medical device that automatically measures glucose levels at regular intervals (typically every 1 to 5 minutes) using a small sensor filament placed subcutaneously in the interstitial fluid, most commonly on the upper arm or abdomen. Unlike a fingerstick test which measures glucose in capillary blood, a CGM measures glucose in the interstitial fluid that bathes cells between blood vessels.

The sensor operates via an electrochemical reaction: glucose in the interstitial fluid reacts with glucose oxidase enzyme coated on the sensor filament, producing a measurable electrical current proportional to glucose concentration. This signal is transmitted wirelessly to a smartphone or dedicated receiver, where software algorithms convert it to a mg/dL or mmol/L reading in real time.

One important characteristic of CGM readings is the physiological lag between interstitial glucose and blood glucose. Because glucose must diffuse from the capillary blood into the interstitial compartment, CGM readings trail behind blood glucose by approximately 10 to 15 minutes. This means a CGM is slightly slower to register a rapid glucose rise after eating than a simultaneous fingerstick would be. For trend monitoring purposes, this lag is clinically insignificant. For acute clinical decisions (dosing insulin, confirming hypoglycemia), a confirmatory fingerstick may be needed.

Several CGM devices are now available to non-diabetics without a prescription in many countries:

• Stelo by Dexcom: The first CGM cleared by the FDA specifically for adults without diabetes. Wears for 15 days and provides over-the-counter access without a prescription in the United States.
• Lingo by Abbott: Based on the FreeStyle Libre platform, designed for wellness monitoring in non-diabetics. Available directly to consumers.
• FreeStyle Libre 3 and Dexcom G7: Prescription devices with higher clinical accuracy, often used by non-diabetics who are working with metabolic health physicians or practitioners.

CGM use by non-diabetics has grown substantially in the biohacking and preventive medicine communities. Research published in Nature Metabolism (Zeevi et al., 2015, Weizmann Institute) demonstrated that glucose responses to identical meals vary dramatically between individuals with identical fasting glucose levels, suggesting that population-average dietary guidelines poorly predict individual postprandial responses. This is one of the primary arguments for personalized CGM-guided nutrition in healthy adults.

The Spectrum of Glucose Metabolism: From Optimal to Diabetic

Glucose metabolism exists on a continuum, not in binary categories. The clinical classifications used by the ADA (American Diabetes Association) define thresholds for diagnosis and treatment, but they were not designed to identify the full range of metabolic dysfunction that precedes formal disease. Understanding where you fall on this spectrum is the first step to meaningful CGM interpretation.

• Optimal metabolic health: Fasting glucose consistently 70 to 85 mg/dL. Postprandial glucose rarely exceeds 110 to 120 mg/dL. Glucose returns to fasting baseline within 90 to 120 minutes of a meal. HbA1c below 5.2%.
• Normal but non-optimal: Fasting glucose 86 to 99 mg/dL. Postprandial peaks reaching 130 to 139 mg/dL. Glucose may take 2 or more hours to return to baseline after high-carbohydrate meals. HbA1c 5.2 to 5.6%.
• Prediabetes (Impaired Fasting Glucose / Impaired Glucose Tolerance): Fasting glucose 100 to 125 mg/dL, or 2-hour OGTT 140 to 199 mg/dL. HbA1c 5.7 to 6.4%. Postprandial glucose regularly exceeds 140 mg/dL.
• Type 2 Diabetes: Fasting glucose at or above 126 mg/dL on two separate tests, or 2-hour OGTT at or above 200 mg/dL, or HbA1c at or above 6.5%.

Critically, a significant proportion of individuals with normal fasting glucose already have compensatory hyperinsulinemia, meaning their pancreas is producing abnormally high levels of insulin to maintain those apparently normal glucose readings. The pioneering clinical work of Joseph Kraft MD, who conducted insulin assays on over 14,000 patients, documented five distinct insulin secretion pattern types. Patterns 2 through 5 represented progressively abnormal insulin responses despite normal glucose tolerance on standard testing. This work suggests that insulin resistance may be present and measurable up to 10 to 20 years before glucose values cross the prediabetes threshold.

For a non-diabetic using a CGM, this means fasting glucose alone is insufficient. The full pattern of how glucose rises, how high it peaks, and how quickly it returns to baseline provides a far more informative picture of metabolic function.

The 7 Key CGM Metrics for Non-Diabetics

1. Time In Range (TIR): The Primary Metric

Time In Range is defined as the percentage of time glucose readings stay within a defined target range over a measurement period, typically 14 days. It has become the leading CGM metric in clinical research, largely replacing simple point-in-time measurements as a reflection of overall glycemic control.

For non-diabetics targeting optimal metabolic health, research and precision medicine practitioners generally recommend aiming for a primary TIR of 70 to 110 mg/dL (3.9 to 6.1 mmol/L) for at least 95% of the 24-hour period. The International Consensus on Time in Range (Battelino et al., 2019, published in Diabetes Care) established TIR targets specifically for diabetic populations (the recommended range for Type 1 and Type 2 diabetes is 70 to 180 mg/dL). For non-diabetics, the target band is considerably tighter, reflecting the higher metabolic sensitivity of a functioning pancreas. Some longevity-focused practitioners set the upper TIR target at 100 mg/dL rather than 110 mg/dL, though this more stringent target is not yet defined by major clinical guidelines.

TIR is a more clinically meaningful metric than average glucose alone because it captures the distribution of glucose values across the day, including nocturnal patterns, early morning variations, and the frequency and depth of postprandial excursions. A 14-day average glucose of 92 mg/dL could result from consistently stable glucose (90% TIR = excellent) or from frequent oscillations between 70 and 120 mg/dL (60% TIR = more concerning).

2. Fasting Glucose Baseline

Fasting glucose (measured after at least 8 hours without caloric intake) represents the minimum daily glucose value and reflects the balance between hepatic glucose output (gluconeogenesis and glycogenolysis) and basal insulin suppression of that output.

For non-diabetic adults:

• Optimal: 70 to 85 mg/dL. Consistently in this range suggests strong hepatic insulin sensitivity and effective overnight glucose regulation.
• Normal upper limit: Below 100 mg/dL. Values in the 86 to 99 mg/dL range are technically non-diagnostic but some research suggests they are associated with higher cardiovascular risk relative to values in the optimal range.
• Impaired Fasting Glucose (IFG): 100 to 125 mg/dL on two separate measurements. This is the ADA's prediabetes fasting threshold and warrants formal medical evaluation.

Consistently elevated overnight fasting glucose (visible on CGM from approximately 3:00 to 6:00 AM) is a specific signal of hepatic insulin resistance. The liver normally suppresses glucose output overnight in response to low-level basal insulin. When this suppression fails, the liver continues releasing glucose into the circulation, producing a rising nocturnal fasting baseline. This pattern is closely associated with non-alcoholic fatty liver disease (NAFLD) and is one of the earliest metabolic signals detectable on continuous monitoring.

3. Postprandial Glucose Peak

Postprandial glucose is the rise in blood glucose following a meal, driven by intestinal absorption of dietary carbohydrates. The peak typically occurs 45 to 75 minutes after meal initiation (variable depending on meal composition, gastric emptying rate, and individual metabolic rate).

For a metabolically healthy non-diabetic, research suggests:

• Optimal peak: Below 120 to 130 mg/dL at 60 minutes post-meal
• Acceptable upper limit: Below 140 mg/dL at 1 hour (the ADA's definition of the threshold above which impaired glucose tolerance is considered present during a 2-hour OGTT)
• Return to baseline: Glucose should return to the pre-meal fasting level within 2 to 2.5 hours

Glucose readings consistently above 140 mg/dL post-meal are clinically significant even in non-diabetics. At glucose levels above 140 mg/dL, the rate of non-enzymatic glycation of proteins and lipids accelerates, oxidative stress increases through mitochondrial superoxide production, and endothelial function is transiently impaired. These effects are short-lived if they occur infrequently, but repeated postprandial excursions above this threshold cumulatively contribute to vascular damage and accelerated biological aging.

4. Glycemic Variability: Coefficient of Variation (CV)

Glycemic variability refers to the magnitude of glucose fluctuations throughout the day, independent of mean glucose level. It is quantified most commonly as the Coefficient of Variation (CV), calculated as the standard deviation of glucose readings divided by the mean glucose, expressed as a percentage.

A CV below 36% is considered optimal even for patients with Type 1 diabetes (Battelino et al., Diabetes Care, 2019). For non-diabetics, lower CV values indicate more stable glucose regulation. High glycemic variability is associated with increased oxidative stress through the formation of reactive oxygen species (ROS) during rapid glucose excursions, independently of mean glucose level. A study published in Cardiovascular Diabetology showed that high intraday glucose variability predicted carotid intima-media thickness progression (an early marker of atherosclerosis) even in individuals whose mean glucose values were within normal range.

Additional variability metrics available on modern CGM software include MAGE (Mean Amplitude of Glycemic Excursions), which specifically quantifies excursions greater than 1 standard deviation from the mean glucose, and the Glucose Management Indicator (GMI), which provides an estimated HbA1c equivalent from 14-day average CGM glucose data.

5. Time Below Range (TBR): Preventing Reactive Hypoglycemia

Time Below Range measures the proportion of time glucose falls below 70 mg/dL (3.9 mmol/L), the clinical threshold for hypoglycemia. Non-diabetics who do not take insulin or sulfonylureas rarely experience spontaneous hypoglycemia, but reactive hypoglycemia (postprandial hypoglycemia) is more common than generally recognized.

Reactive hypoglycemia occurs when a large postprandial insulin response overshoots the carbohydrate load, driving glucose down below 70 mg/dL approximately 1.5 to 3 hours after a high-glycemic meal. Symptoms include shakiness, sweating, palpitations, irritability, difficulty concentrating, and intense carbohydrate cravings. From a physiological standpoint, this hypoglycemic dip activates the hypothalamic-pituitary-adrenal (HPA) axis, triggering a cortisol and glucagon release that re-raises glucose but leaves the individual in a temporarily activated stress state.

For non-diabetic CGM users, the target should be less than 1% of time below 70 mg/dL. Recurrent TBR events despite not taking glucose-lowering medications warrant evaluation for insulinoma, reactive hypoglycemia syndrome, or post-bariatric surgery dumping syndrome.

Dr. Casey Means (co-founder, Levels Health) and Dr. Andrew Huberman (Stanford Neuroscience) on how to interpret CGM data and use glucose monitoring to optimize metabolic health in non-diabetics.

6. The Dawn Phenomenon and Nocturnal Glucose Patterns

The dawn phenomenon describes a natural early-morning rise in blood glucose, typically beginning between 3:00 and 5:00 AM and reaching a peak by 6:00 to 8:00 AM. It is driven by the coordinated action of counter-regulatory hormones: growth hormone (released during deep NREM sleep), cortisol (rising as part of the Cortisol Awakening Response, covered in detail in our companion guide), and glucagon. These hormones stimulate hepatic glucose output to provide fuel for the expected morning activity period.

For a metabolically healthy non-diabetic, the dawn phenomenon results in a modest glucose rise from approximately 75 to 85 mg/dL up to 90 to 100 mg/dL by waking time. A well-functioning insulin secretory system quickly normalizes this rise after awakening. On a CGM, this appears as a gradual upward slope from approximately 3:00 AM that plateaus and then begins declining by mid-morning.

An exaggerated dawn phenomenon, where fasting glucose consistently registers above 100 mg/dL on the CGM before the first meal, signals that the liver's counter-regulatory response is not being adequately suppressed. This is closely associated with hepatic insulin resistance and often precedes or coincides with non-alcoholic fatty liver disease (NAFLD). A separate pattern, the Somogyi effect, involves nocturnal hypoglycemia followed by a rebound hyperglycemia from counter-regulatory hormone release. On a CGM trace, this appears as a glucose dip below 70 mg/dL between midnight and 3:00 AM followed by a sharp morning rise. The Somogyi effect in non-diabetics is uncommon but may occur in individuals with reactive hypoglycemia tendencies.

7. Average Glucose and Estimated HbA1c (GMI)

The Glucose Management Indicator (GMI) is a formula that converts 14-day CGM average glucose into an estimated HbA1c equivalent. It was developed because CGM average glucose and laboratory HbA1c do not always correlate precisely (HbA1c is affected by red blood cell lifespan, variants in hemoglobin, and other factors). The GMI formula is: GMI (%) = 3.31 + 0.02392 x mean glucose (mg/dL).

Standard clinical reference values for HbA1c and their GMI equivalents for non-diabetics:

• Below 5.2% (optimal, precision medicine target): Equivalent CGM average of approximately 103 mg/dL or lower
• 5.2 to 5.6% (normal, above optimal): CGM average approximately 103 to 114 mg/dL
• 5.7 to 6.4% (prediabetes range): CGM average approximately 117 to 137 mg/dL; requires physician evaluation
• 6.5% or above (diabetes range): Formal diabetes evaluation and management required

For non-diabetics using a CGM for optimization purposes, targeting a 14-day average glucose below 100 mg/dL (GMI approximately 5.7% or below) with a consistent TIR above 95% in the 70 to 110 mg/dL range represents a pragmatic, evidence-informed goal for long-term metabolic health preservation. Specific personal targets should always be determined in partnership with a healthcare provider.

The Cellular Mechanism: Why Postprandial Glucose Spikes Cause Harm

Understanding why postprandial glucose spikes matter mechanistically provides the clinical rationale for optimal CGM targets. Three converging pathways explain the cellular damage associated with glucose excursions above 140 mg/dL:

Non-enzymatic glycation and AGE formation. When glucose concentration rises above approximately 140 mg/dL, the rate of Maillard reaction chemistry (non-enzymatic binding of glucose to proteins and lipids) increases substantially. Glucose attaches covalently to free amino groups on hemoglobin (forming HbA1c), collagen fibers (reducing vascular elasticity), apolipoprotein B on LDL particles, and lens proteins in the eye. Over time, these glycated products are further oxidized and cross-linked to form advanced glycation end products (AGEs). AGEs bind to RAGE receptors (Receptor for Advanced Glycation End products) on endothelial cells, smooth muscle cells, and macrophages, triggering NF-kB-mediated inflammatory cascades, reactive oxygen species (ROS) generation, and pro-atherogenic gene expression.

Mitochondrial oxidative stress. Postprandial hyperglycemia drives excessive electron flux through the mitochondrial electron transport chain. When the concentration of glucose-derived NADH overwhelms Complex I and III, electrons leak to molecular oxygen, forming superoxide radicals. This excess superoxide inhibits glyceraldehyde phosphate dehydrogenase (GAPDH), a key glycolytic enzyme, and redirects glucose through damaging side pathways including the polyol pathway, hexosamine pathway, and diacylglycerol-PKC activation. Research from the laboratory of Michael Brownlee at Albert Einstein College of Medicine established this mitochondrial superoxide overproduction as the central unifying mechanism of hyperglycemia-induced vascular damage.

Endothelial nitric oxide synthase (eNOS) uncoupling. Healthy endothelial function depends on eNOS producing nitric oxide (NO), which dilates blood vessels, reduces platelet aggregation, and prevents LDL oxidation. Glucose-induced superoxide rapidly scavenges NO, reducing bioavailable nitric oxide. Simultaneously, oxidative stress uncouples eNOS, causing it to produce superoxide rather than NO. Even a single meal causing a glucose excursion above 140 mg/dL produces measurable endothelial dysfunction detectable by flow-mediated dilation (FMD) studies within 2 hours of the meal, an effect that persists for approximately 4 hours.

Dietary and Behavioral Inputs That Move Your CGM Numbers

Carbohydrate Source and Glycemic Load

The single most powerful dietary lever for controlling postprandial glucose is reducing dietary glycemic load (GL), the product of a food's glycemic index and the amount of carbohydrate consumed. Ultra-processed carbohydrates (white bread, sugary beverages, refined cereals) produce rapid and high postprandial glucose spikes. Intact whole-food carbohydrates with intact fiber matrices (legumes, whole grains, vegetables) produce slower, lower glucose rises due to fiber's viscosity-based slowing of intestinal glucose absorption and its prebiotic fermentation to short-chain fatty acids that improve GLP-1 secretion.

The concept of resistant starch is particularly relevant for CGM users. Resistant starch (RS2 in raw potato starch, RS3 in cooked-then-cooled rice or pasta) passes undigested through the small intestine to the colon, where it serves as prebiotic substrate. Higher dietary resistant starch intake is associated with improved postprandial glucose responses and lower fasting glucose over time.

Meal Sequencing: Vegetables and Protein Before Carbohydrates

A highly practical and evidence-based strategy for reducing postprandial glucose spikes is changing the order in which foods are consumed within a meal. Research by Dr. Alpana Shukla and colleagues at Weill Cornell Medicine, published in Diabetes Care (2015 and 2017), found that eating vegetables and protein sources first, followed by carbohydrates last, reduced the postprandial glucose area under the curve by 29 to 37% compared to consuming carbohydrates first, even when the total nutritional content of the meal was identical.

The mechanism involves multiple pathways: the physical presence of fiber and protein in the stomach and small intestine slows gastric emptying, stimulates the secretion of GLP-1 (glucagon-like peptide 1) and PYY from intestinal L-cells before carbohydrate absorption begins, and pre-amplifies the first-phase insulin response. GLP-1 in particular slows gastric emptying and enhances glucose-stimulated insulin secretion from beta cells, effectively priming the system before the carbohydrate load arrives. This is the natural dietary version of the GLP-1 receptor agonist mechanism that makes drugs like semaglutide so effective.

Post-Meal Walking: The Most Effective Glucose Disposal Protocol

A 10-minute walk after meals consistently ranks among the most effective non-pharmacological interventions for reducing postprandial glucose spikes. Skeletal muscle contraction during walking activates AMP-activated protein kinase (AMPK), which triggers insulin-independent translocation of GLUT4 glucose transporters to the skeletal muscle cell surface. This bypasses the standard insulin receptor phosphorylation cascade, creating an alternative glucose disposal pathway that does not depend on insulin sensitivity.

A study published in Diabetes Care (2013, van Dijk JW et al.) found that 45 minutes of moderate-intensity exercise in the postprandial period significantly attenuated the glucose and insulin responses to a high-GI meal. More practically applicable data from DiabetesCare and subsequent wearable-device studies have shown that even a 10-minute walk at a comfortable pace within 30 minutes of meal completion reduces 2-hour postprandial glucose by an average of 15 to 20% compared to remaining sedentary. On a CGM trace, this appears as a flattening of the postprandial curve and a more rapid return to the pre-meal baseline.

Sleep Quality and Morning Glucose: The Upstream Connection

The quality of the preceding night's sleep substantially affects the following day's glucose regulation. Sleep deprivation reduces insulin sensitivity in skeletal muscle and hepatic tissues via multiple mechanisms including elevated morning cortisol (which drives hepatic gluconeogenesis) and elevated growth hormone (which promotes lipolysis and the resulting free fatty acid-driven hepatic insulin resistance). Even partial sleep restriction (5 to 6 hours versus 7 to 8 hours) has been shown in controlled studies to increase postprandial glucose responses and reduce insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. Use the Sleep Debt Calculator to track whether accumulated sleep debt may be contributing to elevated CGM readings.

Dr. Robert Lustig (UCSF) on the biochemistry of fructose metabolism, hepatic glucose processing, and the mechanisms linking dietary sugar to insulin resistance and metabolic disease.

Interpreting CGM Patterns: A Practical Reference

Raw CGM data becomes clinically useful when interpreted as patterns rather than isolated data points. The following patterns are the most common and clinically meaningful for non-diabetic CGM users:

CGM Pattern	Clinical Significance	Primary Action
Flat stable trace, fasting 70-85, peaks below 120 mg/dL	Excellent metabolic flexibility and insulin sensitivity	Maintain current diet, sleep, and movement patterns
Peaks to 130-139 mg/dL, returns to baseline by 2 hours	Normal response to higher-GI meals; insulin secretory capacity intact	Consider glycemic load reduction for consistently spiking meals
Consistent peaks above 140 mg/dL, slow 2.5+ hour return	Postprandial glucose intolerance; potential early insulin resistance	Implement meal sequencing, post-meal walking; consult a physician
Fasting glucose consistently 90-99 mg/dL before first meal	Suboptimal fasting baseline; may indicate early hepatic insulin resistance	Address diet quality, sleep debt, visceral fat; discuss with physician
Glucose dipping below 70 mg/dL 1.5-3 hours post-meal	Reactive hypoglycemia; exaggerated postprandial insulin response	Reduce meal glycemic load; evaluate with a physician if recurrent
High nocturnal glucose 100-115 mg/dL during sleep, before waking	Excessive hepatic glucose output; strong indicator of hepatic insulin resistance	Assess for NAFLD; reduce dietary fructose and refined carbohydrates; consult a physician

Using the Health is Heaven Tools to Act on Your CGM Data

CGM data is most powerful when combined with validated metabolic risk tools that contextualise your readings within your broader health picture. Health is Heaven provides two directly relevant calculators:

The Blood Sugar Checker allows you to log fasting, pre-meal, post-meal, and bedtime glucose readings and receive interpretation guidance calibrated to your specific reading context. Unlike a CGM which provides raw data, the Blood Sugar Checker flags readings relative to clinical reference ranges and explains what each value may indicate about your glucose metabolism status.

The Diabetes Risk Assessment evaluates your overall type 2 diabetes risk based on established risk factors including age, BMI, family history, physical activity level, and blood pressure. If your CGM is consistently showing patterns in the yellow or orange zones in the table above, completing the Diabetes Risk Assessment will help you quantify whether a formal medical evaluation is warranted. A high-risk score combined with suboptimal CGM patterns is a clear signal to discuss evaluation with a physician.

When to Consult a Healthcare Professional

CGM monitoring provides valuable self-knowledge, but it does not replace clinical evaluation. Seek professional assessment if you observe any of the following on your CGM or in your overall health history:

• Fasting glucose consistently at or above 100 mg/dL on 14-day CGM average
• Postprandial glucose regularly exceeding 180 mg/dL after typical meals
• Any glucose reading below 55 mg/dL, which may indicate a significant hypoglycemic event requiring investigation
• Nocturnal glucose consistently above 110 mg/dL during sleep despite no recent food intake
• HbA1c result at or above 5.7% on laboratory testing
• Family history of Type 2 diabetes combined with overweight, physical inactivity, or high waist circumference
• Symptoms of hyperglycemia: persistent thirst, frequent urination, unexplained fatigue, or blurred vision
• Symptoms of recurrent hypoglycemia: shakiness, palpitations, brain fog 1 to 3 hours after meals on a regular basis

Diagnostic tests used to formally evaluate glucose metabolism include fasting plasma glucose (FPG), 2-hour oral glucose tolerance test (OGTT), HbA1c, and fasting insulin (for HOMA-IR calculation, which quantifies insulin resistance). CGM data can be shared with your physician to enrich this evaluation with pattern data not captured by point-in-time tests.

Frequently Asked Questions

What is the ideal CGM range for a healthy non-diabetic?

For a metabolically healthy non-diabetic adult, optimal CGM targets include a fasting glucose of 70 to 85 mg/dL, postprandial peaks below 120 to 130 mg/dL returning to baseline within 2 hours, and Time In Range (70 to 110 mg/dL) exceeding 95% of the day. These targets are more stringent than the clinical prediabetes thresholds and reflect a proactive approach to long-term metabolic health. Individual targets should be discussed with a healthcare provider.

Should healthy people without diabetes wear a CGM?

CGM use by non-diabetics has grown with the availability of over-the-counter sensors. The primary benefit is identifying food-specific postprandial responses and recognizing early glycemic variability patterns before clinical thresholds are crossed. Research published in Nature Metabolism has shown highly individual glucose responses to identical meals even among healthy adults. However, CGM data can create unnecessary health anxiety in some individuals, and clinical utility for otherwise low-risk healthy adults remains debated. Consult a physician to determine if CGM monitoring is appropriate for your context.

What does it mean if my glucose spikes to 150 mg/dL after a meal?

A postprandial peak of 150 mg/dL is above the 140 mg/dL threshold associated with impaired glucose tolerance and suggests a significant glycemic load relative to current insulin capacity or sensitivity. Occasional peaks after unusually large high-GI meals may occur in otherwise healthy individuals, but recurrent spikes above 140 mg/dL at 1 hour post-meal warrant attention. Meal sequencing, reducing refined carbohydrate intake, and a post-meal walk may help. Persistent patterns above this threshold should be discussed with a physician.

How accurate are CGM readings compared to fingerstick blood tests?

CGMs measure glucose in interstitial fluid with a 10 to 15 minute physiological lag behind blood glucose. Modern devices (Dexcom G7, FreeStyle Libre 3) report a Mean Absolute Relative Difference (MARD) of approximately 8 to 9%. Accuracy can be affected by sensor site, movement, temperature extremes, and compression. CGM provides valuable trend data, but clinical decisions should not be based on a single CGM reading when precision matters.

What is the difference between prediabetes and insulin resistance on a CGM?

Prediabetes is a clinical diagnosis defined by fasting glucose of 100 to 125 mg/dL, 2-hour OGTT of 140 to 199 mg/dL, or HbA1c of 5.7 to 6.4%. Insulin resistance is a physiological state that often precedes prediabetes by years. In early insulin resistance, the pancreas compensates with higher insulin output to maintain normal glucose, so fasting glucose may still appear normal below 100 mg/dL. A CGM can detect early insulin resistance indirectly through elevated postprandial peaks and slow glucose return to baseline. Formal testing requires a fasting insulin level or HOMA-IR calculation.

Scientific References and Endocrine Sources

• Battelino T et al. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 42(8), 1593-1603.
• Zeevi D et al. (2015). Personalized nutrition by prediction of glycemic responses. Cell, 163(5), 1079-1094. (Weizmann Institute / Segal lab)
• Shukla AP et al. (2017). Food order has a significant impact on postprandial glucose and insulin levels. Diabetes Care, 40(7), e106-e107. (Weill Cornell Medicine)
• Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
• American Diabetes Association (2026). Standards of Medical Care in Diabetes - Classification and Diagnosis. Diabetes Care, 49 (Suppl. 1). Available at diabetes.org
• Journal of Clinical Endocrinology and Metabolism: Access peer-reviewed endocrinology and glucose metabolism research.

---